EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Retinal Degeneration - Pipeline Review, H1 2015

  • ID: 3293099
  • Report
  • May 2015
  • 82 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aprogen, Inc.
  • BBB Therapeutics B.V.
  • Bionature E.A. Ltd.
  • Biovista Inc.
  • GenSight Biologics SA
  • SanBio, Inc.
  • MORE
Retinal Degeneration - Pipeline Review, H1 2015

Summary

This, ‘Retinal Degeneration - Pipeline Review, H1 2015’, provides an overview of the Retinal Degeneration’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinal Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinal Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinal Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aprogen, Inc.
  • BBB Therapeutics B.V.
  • Bionature E.A. Ltd.
  • Biovista Inc.
  • GenSight Biologics SA
  • SanBio, Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Retinal Degeneration Overview
Therapeutics Development
Pipeline Products for Retinal Degeneration - Overview
Pipeline Products for Retinal Degeneration - Comparative Analysis
Retinal Degeneration - Therapeutics under Development by Companies
Retinal Degeneration - Therapeutics under Investigation by Universities/Institutes
Retinal Degeneration - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Retinal Degeneration - Products under Development by Companies
Retinal Degeneration - Products under Investigation by Universities/Institutes
Retinal Degeneration - Companies Involved in Therapeutics Development
Alkeus Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Aprogen, Inc.
BBB Therapeutics B.V.
Bionature E.A. Ltd.
Biovista Inc.
GenSight Biologics SA
SanBio, Inc.
Santhera Pharmaceuticals Holding AG
Senju Pharmaceutical Co., Ltd.
Spark Therapeutics, Inc.
Retinal Degeneration - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AP-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVA-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVA-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Lebers Hereditary Optic Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Choroideremia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Retinal Degenerative Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Retinoschisin for X-Linked Retinoschisis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idebenone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MTP-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAAV2tYFCB-hRS1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-623 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 8 for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Inherited Retinal Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Neurotrophin Receptor for CNS and Ophthalmological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNC-121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNJ-1945 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinal Degeneration - Recent Pipeline Updates
Retinal Degeneration - Dormant Projects
Retinal Degeneration - Dormant Projects
Retinal Degeneration - Product Development Milestones
Featured News & Press Releases
Jun 05, 2014: European Medicines Agency Validates Santhera’s Marketing Authorization Application for Raxone in Leber’s Hereditary Optic Neuropathy
May 07, 2014: Santhera Files Marketing Authorization Application in European Union for Raxone in the Treatment of LHON
Mar 04, 2014: Santhera Presents New Efficacy Data from an Expanded Access Program with Raxone for the Treatment of Leber's Hereditary Optic Neuropathy
Jan 21, 2014: Temporary Authorization for Use Granted for Santhera's Raxone for the Treatment of Leber's Hereditary Optic Neuropathy in France
Mar 22, 2013: Santhera Pharma Withdraws Marketing Authorization Application For Raxone In LHON
Jan 18, 2013: Santhera Pharma Receives Negative Opinion From EMA's CHMP On Marketing Authorization Application For Raxone
Nov 16, 2012: Santhera Pharma Expects CHMP Opinion On MAA For Raxone In Early 2013
Jul 26, 2011: Catena Improves Sight For Patients With Inherited Blindness, Newcastle University Study Finds
Jul 22, 2011: EMA Accepts Santhera's Marketing Authorization Application Of Idebenone For Review In LHON
Jun 06, 2011: Santhera Pharma Presents Nonclinical Data In LHON At Joint Congress Of SOE/AAO 2011
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Retinal Degeneration, H1 2015
Number of Products under Development for Retinal Degeneration - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Retinal Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H1 2015
Retinal Degeneration - Pipeline by Applied Genetic Technologies Corporation, H1 2015
Retinal Degeneration - Pipeline by Aprogen, Inc., H1 2015
Retinal Degeneration - Pipeline by BBB Therapeutics B.V., H1 2015
Retinal Degeneration - Pipeline by Bionature E.A. Ltd., H1 2015
Retinal Degeneration - Pipeline by Biovista Inc., H1 2015
Retinal Degeneration - Pipeline by GenSight Biologics SA, H1 2015
Retinal Degeneration - Pipeline by SanBio, Inc., H1 2015
Retinal Degeneration - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015
Retinal Degeneration - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015
Retinal Degeneration - Pipeline by Spark Therapeutics, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Retinal Degeneration Therapeutics - Recent Pipeline Updates, H1 2015
Retinal Degeneration - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Retinal Degeneration, H1 2015
Number of Products under Development for Retinal Degeneration - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Alkeus Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Aprogen, Inc.
BBB Therapeutics B.V.
Bionature E.A. Ltd.
Biovista Inc.
GenSight Biologics SA
SanBio, Inc.
Santhera Pharmaceuticals Holding AG
Senju Pharmaceutical Co., Ltd.
Spark Therapeutics, Inc.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll